Promedius raises US$18M Series B to scale AI osteoporosis screening
What's the deal? South Korean medical AI startup Promedius has closed a US$18M Series B round — more than double its original target. The raise brings total funding past US$29.3M.
Daewoong PharmaceuticalDealroom has a profile for this one. Try Dealroom → and NaverDealroom has a profile for this one. Try Dealroom → joined as strategic investors alongside returning backers Starset InvestmentDealroom has a profile for this one. Try Dealroom → and Woori Venture PartnersDealroom has a profile for this one. Try Dealroom →. New financial investors include Kolon InvestmentDealroom has a profile for this one. Try Dealroom →, SL InvestmentDealroom has a profile for this one. Try Dealroom →, Quad Asset ManagementDealroom has a profile for this one. Try Dealroom →, and IBK Industrial Bank of KoreaDealroom has a profile for this one. Try Dealroom →, among others.
Why now? Promedius's flagship product, Osteo Signal, hit key regulatory milestones in quick succession. It was designated an innovative medical device in 2024, received approval from South Korea's Ministry of Food and Drug Safety in 2025, and was selected as a new medical technology with deferred evaluation earlier this year — opening the door to domestic commercialisation.
The tool uses AI to analyse routine chest X-rays and flag osteoporosis risk within three seconds, no additional scans required. That matters because osteoporosis is largely silent until a fracture occurs, and access to DXA — the standard bone density test — remains limited worldwide.
Promedius has already secured regulatory clearance in Vietnam and Indonesia and is pursuing US FDA and European CE MDR approvals this year. It is also expanding partnerships with global medtech firms including Siemens HealthineersDealroom has a profile for this one. Try Dealroom →.
What could go wrong? FDA and CE MDR approvals are notoriously unpredictable in timeline and outcome. Competing AI radiology startups are also eyeing opportunistic screening use cases, which could crowd the field before Promedius establishes a foothold in Western markets.
Reimbursement is another hurdle. Without payer coverage, hospital adoption often stalls — and Promedius is currently limited to the non-reimbursable market even in its home country.
The signal: Promedius is still at the early growth stage, yet it pulled in more than double its fundraising target — a sign of strong investor conviction in opportunistic AI screening as a category. The participation of two corporates, Daewoong Pharmaceutical and Naver, points to a "screen-to-treat" thesis: Daewoong brings an existing osteoporosis drug portfolio and hospital network, while Naver offers digital health distribution, creating a pipeline that runs from AI detection straight through to treatment and patient engagement.
Read more: venturesquare.net
